Martin Hosking
Head of ResearchDr. Martin Hosking serves as Head of Research of Fate Therapeutics, Inc. from 2026. Dr. Hosking is responsible for overseeing and advancing the development of iPSC-derived immune cell therapies to clinical evaluation for patients with cancer and autoimmune diseases. With more than two decades of research and leadership experience spread across academia and biotechnology, Dr. Hosking has co-authored numerous studies and patents related to the generation, regulation and maintenance of immune cell responses to cancer and viruses. Dr. Hosking has B.S. in Molecular Biology, Biochemistry, Biological Sciences from University of California, Irvine. Dr. Hosking has Ph.D. in Molecular Biology, Biochemistry, Biological Sciences from University of California, Irvine.
Positions
- Company NameFate Therapeutics, Inc.Stock CodeFATEPositionHead of ResearchColleagues
- BVBahram ValamehrPresident, CEO & Director
- WHWilliam H. RastetterIndependent Chairman
- KAKamal AdawiCFO & Treasurer
- CRCindy R. TahlChief Legal & Compliance Officer and Corporate Secretary
- JFJessica FrancisSenior Vice President of Human Resources & Operations
- RSRobert S. EpsteinIndependent Director
- KJKarin JoossIndependent Director
- MCMatthew C. AbernethyIndependent Director
